Analysts

Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$ 5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:NGEN) after the company said it had completed its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, clearing the way for the Phase 3 RESTORE trial in chronic tetraplegia. Uddin […]

AI Analysts pink

Perimeter Medical Imaging wins price target raise from this analyst

In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI (Perimeter Medical Imaging AI Stock Quote, Chart, News, Analysts, Financials TSXV:PINK) and raised his target to C$0.95 from C$0.70 after fourth-quarter results and recent M&A activity in breast cancer surgery. McAuley said Perimeter’s FDA-cleared Claire device […]

Get Stock Picks from the Pros.
In your Inbox.

Byron Capital healthcare analyst Douglas Loe believes that allergy treatment Oralair could become a leading product in Paladin Labs' already diverse offering.

Analysts Life Sciences plb

Byron Capital’s Loe says Oralair Makes Paladin Less Risky, Reiterates Buy

March 22, 2012

Paladin Labs (TSX:PLB) yesterday announced it has received approval from Health Canada for it grass ...

Inside a full scale model interior of a Bombardier CSeries. Byron Capital analyst Tom Astle says the company's commercial aircraft business has been a drag on overall valuation, but may be improved by it recent deal with the Commercial Aircraft Corporation of China.

Analysts Hardware bbd bbd.b

Byron Capital’s Astle says Bombardier’s COMAC Deal Reduces Risk

March 21, 2012

Bombardier (TSX:BBD.B) today provided some detail on the agreement it signed with the government own...

Analysts Life Sciences

Merck drops Cardiome, Byron Capital’s Loe Slashes Target

March 19, 2012

Some surprising news from Cardiome (TSX:COM) today as the company announced that Merck will disconti...

In a research update Tuesday, Versant analyst Tom Liston says a management shakeup at Wireless Matrix probably came about because of

Analysts Software wrx

Despite Management Shakeup, Versant’s Liston Still Lukewarm on Wireless Matrix

March 16, 2012

A shuffle at Wireless Matrix (TSX:WRX) this week as the company announced that J. Richard Carlson, w...

Think border lineups are bad now? Without Waterloo's Descartes Systems they'd be a whole lot worse.

Analysts Software dsg

M Partners Shuttleworth Raises Target on Descartes to $12

March 9, 2012

Descartes Systems Group (TSX:DSG) yesterday reported its fiscal 2012 results. Revenue was up 15% fro...

Wi-LAN CEO Jim Skippen. Byron Capital analyst Tom Astle says new and current patent portfolio combined with current and upcoming litigation activity could drive Wi-LAN's revenue growth by 25% in 2013.

Analysts Wireless win

Byron Capital’s Tom Astle Says Wi-LAN’s Growth Likely Not Done

March 7, 2012

Wi-LAN (TSX:WIN) today reported its fiscal 2011 results. The company’s topline of $105.8-milli...

With a quarter-million users as of November 8th, more than three times the number the company expected, Transgaming's GameTreeTV is, after numerous delays, a hit.

Analysts Gaming Software tng

M Partners Initiates Coverage of TransGaming with a BUY, $1 Target

March 6, 2012

Until now, the story of TransGaming (TSXV:TNG) has been one of incremental gains. The Toronto compan...

IMRIS CEO David Graves. On Friday, Byron Capital Healthcare Analyst Douglas Loe reiterated his BUY rating and $8 target on the stock.

Analysts Hardware Life Sciences im

Byron Capital’s Loe says Despite Soft Quarter IMRIS Still a Buy

March 3, 2012

On Thursday, IMRIS (TSX:IM) reported its Q4 and fiscal 2011 results. Across the board, the numbers w...

On Wednesday, Algonquin Power announced it had secured a twenty-five year Power Purchase agreement with Sask Power for a 177 megawatt wind power project, beating out twenty-seven other proposals.

Analysts Cleantech aqn

M Partners John Safrance raises target on Algonquin Power

March 1, 2012

On Wednesday, Algonquin Power (TSX:AQN) announced it had secured a twenty-five year Power Purchase a...

Byron Capital analyst Tom Astle says that while there are many caveats to be aware of with Bombardier and its balance sheet, there appears to be more upside than downside in its share price.

Analysts Hardware bbd.b

Byron Capital’s Tom Astle likes Bombardier. Or Does He?

February 21, 2012

On the first day of December last year, Bombardier (TSX:BBD.B) reported its Q3, 2011 results. The Ca...

Dr. Yves Fradet, President of Diagnocure. On Wednesday, Byron Capital analyst Douglas Loe upgraded the company to Buy from Speculative Buy because he says Diagnocure is no longer as subject to clinical or regulatory risk.

Analysts Life Sciences cur

Byron Capital’s Douglas Loe Raises Target Price on Diagnocure

February 18, 2012

This past Wednesday DiagnoCure (TSX:CUR), along with its US-based partner Gen-Probe, received FDA ap...

Dacryocytes, or teardrop-shaped cells, are found in myelofibrosis and myelophthisic states of bone marrow. Mississauga's YM Bioscience's Myelofibrosis treatment, CYT387, has performed well in Phase Two trials. Byron Capital Healthcare analyst Douglas Loe thinks this may soon attract a larger

Analysts Life Sciences ym

Byron Capital’s Loe: Things Could Start to Get Interesting for YM Biosciences

February 13, 2012

Last Thursday, YM Biosciences (TSX:YM) reported its Q2, 2012 results. The company lost $6.55-million...

Open Text's Q2 signals the end of the John Shackleton era and the beginning of the Mark Barrenechea era. On January 2nd, the former President and CEO of Rackable took the helm at Waterloo's second most well known company.

Analysts Software OTC

Open Text beats the Street, Versant raises target to $70

February 5, 2012

On Wednesday, Waterloo’s Open Text (TSX:OTC) surprised the street with a particularly strong Q...

Byron Capital analyst Tom Astle says there are are similarities and important differences between Thorsten Heins at RIM and Mike Zafirovski's introduction as Nortel CEO in November of 2005.

Analysts RIM nt rim

RIM’s Thorsten Heins Meets Bay Street Analysts. Is this Nortel 2.0?

February 4, 2012

This past Thursday, in the basement of a steakhouse in Toronto, new Research in Motion CEO Thorsten ...

Analysts Lists and Data aah abt axx dsg gln so SVC vcm

Facebook IPO Spotlights US Tech, but Canadian Techs are More Profitable

February 1, 2012

Social media juggernaut Facebook today filed its IPO papers. The offering, which will be underwritte...

Analysts OTC

In Davos, Stephen Harper calls on Open Text’s Jenkins for Innovation Advice

January 27, 2012

It wasn’t potash, or gold, or even lumber. Today at the World Economic Forum in Davos, Switzer...

Will the rumoured May IPO of Facebook bring even more attention to social media stocks like Calgary's Poynt? Analyst Byron Berry says he is struck by the similarities between Poynt and San Francisco based IPO candidate Yelp.

Analysts pyn

Analyst Byron Berry: Poynt and Yelp aren’t so Different

January 26, 2012

In the public markets, the social media frenzy that will no doubt reach its pinnacle with the IPO of...

Last Friday, in a U.S. district court in Florida, Ottawa's Wi-LAN launched a patent suit against Research in Motion.

Analysts Wireless rim win

Wi-LAN sues Research in Motion, Byron Capital Reiterates $7 Buy Target

January 23, 2012

On Friday, about forty-eight hours before the surprising news broke that Thorsten Heins was named ne...

Analysts

TRENDING

AI won’t kill Lumine Group, this analyst says

Kinaxis named a “Top Pick” for 2026 by this analyst

This investor never liked Constellation Software. He does now.

This cannabis stock is a “Top Pick” for 2026, analyst says

Is Trulieve Cannabis a buy right now?